Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00011128
Status:
WITHDRAWN
Last Update Posted:
2015-05-18
First Post:
2001-02-10
Brief Title:
Salvage Treatment Resistance Testing and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Phase III Evaluation of the Role of Temporary Cessation of Antiretroviral Treatment and Resistance Testing-Based Selection of Antiretroviral Drugs in the Virologic Response to Salvage Therapy for Heavily Treatment-Experienced HIV-Infected Individuals Failing Current Antiretroviral Therapy
Status:
WITHDRAWN
Status Verified Date:
2004-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test another way to control the amount of HIV in the blood viral load
Studies show that stopping all anti-HIV drugs for a time before switching to new anti-HIV drugs may improve the response in some individuals who are failing treatment Other studies suggest a benefit if drug-resistance tests are used in selecting a new anti-HIV drug treatment This study tests the effect of stopping anti-HIV drugs for a time before switching to anti-HIV drugs selected using drug-resistance test results
Studies show that stopping all anti-HIV drugs for a time before switching to new anti-HIV drugs may improve the response in some individuals who are failing treatment Other studies suggest a benefit if drug-resistance tests are used in selecting a new anti-HIV drug treatment This study tests the effect of stopping anti-HIV drugs for a time before switching to anti-HIV drugs selected using drug-resistance test results
Detailed Description:
Virologic failure occurs in a large proportion of individuals receiving treatment with combination antiretroviral therapy Studies suggest that treatment interruption prior to initiation of a multiple-drug rescue regimen may improve virologic response in individuals who have failed several prior antiretroviral regimens Other studies suggest there is a virologic benefit derived from using genotypic or phenotypic resistance testing in selecting salvage therapy regimens for patients failing antiretroviral therapy This study tests the hypothesis that salvage regimens selected on the basis of HIV-1 resistance genotype phenotype AS PER AMENDMENT 021902 virtual phenotype and treatment history will be more effective if there is a period of treatment interruption before initiating that regimen
Patients continue their antiretroviral therapy until randomization Based on the results of the pre-entry genotype and phenotype AS PER AMENDMENT 021902 virtual phenotype tests and treatment history an individualized salvage therapy regimen not provided by the study is selected by the site investigators Additionally patients start or continue maintenance therapy not provided by the study for opportunistic infections OIs Patients are randomized to 1 of 2 treatment arms In Arm A patients have antiretroviral treatment interruption for a period of 16 weeks Step 1 followed by initiation of the AS PER AMENDMENT 021902 best available salvage therapy regimen Step 2 AS PER AMENDMENT 021902 Patients in Arm A will be placed immediately on their individualized salvage regimen before the end of the 16-week period of treatment interruption if their CD4 count falls below a defined threshold or if they develop a new OI In Arm B patients switch immediately to the salvage therapy regimen AS PER AMENDMENT 021501 Patients who become pregnant during Step 1 of Arm A must be advised to begin their selected individualized salvage therapy regimen or a modified salvage regimen Patients who become pregnant during Step 2 of Arm A or Arm B have therapy evaluated and undergo any changes required by their pregnancy Patients in both arms are monitored for plasma HIV-1 RNA levels CD4 and CD8 cell counts and HIV drug resistance genotypes and phenotypes for a duration of 64 weeks from randomization Patients in Arm A are also monitored for immune reactivation by measurement of T-cell subsets and plasma cytokines during treatment interruption Patients may participate in a virology substudy A5100s and an immunology substudy A5104s AS PER AMENDMENT 021902 Patients who volunteer to participate in the substudies must be registered to the main study at the same time they are registered to a substudy
Patients continue their antiretroviral therapy until randomization Based on the results of the pre-entry genotype and phenotype AS PER AMENDMENT 021902 virtual phenotype tests and treatment history an individualized salvage therapy regimen not provided by the study is selected by the site investigators Additionally patients start or continue maintenance therapy not provided by the study for opportunistic infections OIs Patients are randomized to 1 of 2 treatment arms In Arm A patients have antiretroviral treatment interruption for a period of 16 weeks Step 1 followed by initiation of the AS PER AMENDMENT 021902 best available salvage therapy regimen Step 2 AS PER AMENDMENT 021902 Patients in Arm A will be placed immediately on their individualized salvage regimen before the end of the 16-week period of treatment interruption if their CD4 count falls below a defined threshold or if they develop a new OI In Arm B patients switch immediately to the salvage therapy regimen AS PER AMENDMENT 021501 Patients who become pregnant during Step 1 of Arm A must be advised to begin their selected individualized salvage therapy regimen or a modified salvage regimen Patients who become pregnant during Step 2 of Arm A or Arm B have therapy evaluated and undergo any changes required by their pregnancy Patients in both arms are monitored for plasma HIV-1 RNA levels CD4 and CD8 cell counts and HIV drug resistance genotypes and phenotypes for a duration of 64 weeks from randomization Patients in Arm A are also monitored for immune reactivation by measurement of T-cell subsets and plasma cytokines during treatment interruption Patients may participate in a virology substudy A5100s and an immunology substudy A5104s AS PER AMENDMENT 021902 Patients who volunteer to participate in the substudies must be registered to the main study at the same time they are registered to a substudy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AACTG A5086 | None | None | None |
| Substudy AACTG A5100s | None | None | None |
| Substudy AACTG A5104s | None | None | None |